HRP20160221T1 - Serum amiloidni p derivati i njihova priprema i upotreba - Google Patents
Serum amiloidni p derivati i njihova priprema i upotreba Download PDFInfo
- Publication number
- HRP20160221T1 HRP20160221T1 HRP20160221T HRP20160221T HRP20160221T1 HR P20160221 T1 HRP20160221 T1 HR P20160221T1 HR P20160221 T HRP20160221 T HR P20160221T HR P20160221 T HRP20160221 T HR P20160221T HR P20160221 T1 HRP20160221 T1 HR P20160221T1
- Authority
- HR
- Croatia
- Prior art keywords
- sap polypeptide
- polypeptide
- linked
- amino acid
- human sap
- Prior art date
Links
- 210000002966 serum Anatomy 0.000 title claims 6
- 238000002360 preparation method Methods 0.000 title claims 4
- 229920001184 polypeptide Polymers 0.000 claims 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims 60
- 108090000765 processed proteins & peptides Proteins 0.000 claims 60
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 claims 36
- 150000002482 oligosaccharides Polymers 0.000 claims 26
- 238000000034 method Methods 0.000 claims 22
- 125000005629 sialic acid group Chemical group 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 230000002255 enzymatic effect Effects 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 230000004075 alteration Effects 0.000 claims 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- 210000000630 fibrocyte Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000001616 monocyte Anatomy 0.000 claims 3
- 108010085220 Multiprotein Complexes Proteins 0.000 claims 2
- 102000007474 Multiprotein Complexes Human genes 0.000 claims 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000001311 chemical methods and process Methods 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 230000004807 localization Effects 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000893 fibroproliferative effect Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Claims (38)
1. Glikolizirani humani serum amiloid P (SAP) polipeptid koji sadržava oligosaharidni lanac vezan na N, naznačen time, da najmanje jedan ogranak oligosaharidnog lanca završava s kiselinskim dijelom sijalične kiseline vezanim na α2,3.
2. Glikozilirani humani SAP polipeptid u skladu s patentnim zahtjevom 1, naznačen time, da polipeptid sadržava aminokiselinsku sekvencu koja je najmanje 85% identična aminokiselinskoj sekvenci SEQ ID NO: 1.
3. Glikozilirani humani SAP polipeptid u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da oligosaharidni lanac vezan na N sadržava pentasaharidnu jezgru Man[(α1,6-)-(Man(α1,3)]-Man(�1,4)-GlcNAc(�1,4)-GlcNAc(�1,N)-Asn.
4. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da oligosaharidni lanac sadržava najmanje jednu granu koja ima strukturu NeuNAc2a3Gal�4GlcNAc�2Manα6
5. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da je SAP polipeptid rekombinantni polipeptid.
6. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da polipeptid sadržava aminokiselinsku sekvencu koja je najmanje 90% identična aminokiselinskoj sekvenci SEQ ID NO: 1.
7. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da polipeptid sadržava aminokiselinsku sekvencu koja je najmanje 95% identična aminokiselinskoj sekvenci SEQ ID NO: 1.
8. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da polipeptid sadržava aminokiselinsku sekvencu koja je najmanje 96% identična sekvenciji aminokiselina iz SEQ ID'NO: 1.
9. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da polipeptid sadržava aminokiselinsku sekvencu koja je najmanje 98% identična aminokiselinskoj sekvenci SEQ ID NO: 1.
10. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da polipeptid sadržava aminokiselinsku sekvencu koja je najmanje 99% identična aminokiselinskoj sekvenci SEQ ID NO: 1.
11. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da polipeptid sadržava aminokiselinsku sekvencu SEQ ID NO:1.
12. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time, da je polipeptid fuzijski protein koji sadržava domenu SAP i jednu ili više heterolognih domena.
13. Glikozilirani humani SAP polipeptid u skladu s patentnim zahtjevom 12, naznačen time, da jedna ili više heterolognih domena povećavaju jedno ili više od sljedećih svojstava: in vivo stabilnost, vrijeme in vivo polu-života, unos/primjenu, tkivnu lokalizaciju ili distribuciju, formiranje proteinskih kompleksa I / ili pročišćavanje.
14. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time, da polipeptid sadržava jedan ili više modificiranih aminokiselinskih ostataka.
15. Glikozilirani humani SAP polipeptid u skladu s patentnim zahtjevom 14, naznačen time, da jedan ili više modificiranih aminokiselinskih ostataka obuhvaća PEGilirane amilno kiseline, preniliranu amino kiselinu, acetiliranu aminokiselinu, biotiniliranu aminokiselinu, i/ili amino kiselinu konjugiranu na organsko derivatizirajuće sredstvo.
16. Glikozilirani humani SAP polipeptid u skladu s patentnim zahtjevom 15, naznačen time, da jedan amino kiselinski ostatak ili više aminokiselinskih ostataka povećava in vivo stabilnost, vrijeme in vivo polu-života, unos / primjenu, tkivnu lokalizaciju ili distribuciju, formiranje proteinskih kompleksa i / ili pročišćavanje.
17. Farmaceutski pripravak prikladan za upotrebu kod sisavaca, naznačen time, da sadržava humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 16 i farmaceutski prihvatljivu podlogu.
18. Postupak za dobivanje humanog SAP polipeptida koji sadržava oligosaharidni lanac vezan na N, pričemu najmanje jedan ogranak oligosaharidnog lanca završava s kiselinskim dijelom sijalične kiseline vezanim na α2,3, naznačen time, da postupak obuhvaća:
i) ekspresiju ljudskog SAP polipeptida u stanici; i
ii) izolaciju ljudskog SAP polipeptida iz stanice.
19. Postupak u skladu s patentnim zahtjevom 18, naznačen time, da je stanica CHO stanica.
20. Postupak u skladu s patentnim zahtjevom 18 ili 19, naznačen time, da je SAP polipeptid polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 16.
21. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 5, 7 ili 12 do 16 ili postupak u skladu s bilo kojim od patentnih zahtjeva 18 do 20, naznačen time, da sve grane oligosaharidnog lanca završavaju s kiselinskim dijelom sijalične kiseline vezanim na α2,3.
22. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 5, 7 ili 12 do 16 ili postupak u skladu s bilo kojim od patentnih zahtjeva 18 do 20, naznačen time, da je oligosaharidni lanac u biti bez kiselinskih ostataka sijalične kiseline vezanih na α2,3.
23. Postupak u skladu s patentnim zahtjevom 18, naznačen time, da nadalje obuhvaća enzimske ili kemijske promjene izoliranog SAP polipeptida da bi se proizveo SAP polipeptid s modificiranim oligosaharidnim lancem.
24. Postupak u skladu s patentnim zahtjevom 23, naznačen time, da enzimski ili kemijski proces promjene izoliranog SAP polipeptida uklanja jednu ili više završnih
25. Postupak u skladu s patentnim zahtjevom 24, naznačen time, da enzimski ili kemijski proces promjene izoliranog SAP polipeptida zamjenjuje jednu ili više završnih skupina sijalične kiselina vezanih na α2,6 oligosaharidnog lanca s jednom ili više skupina sijalične kiselina vezanih na α2,3.
26. Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili postupak u skladu s bilo kojim od patentnih zahtjeva 18 do 25, naznačen time, da izolirani SAP polipeptid ima IC50 za inhibiciju diferencijacije monocita u fibrocite in vitro koja je manja od jedne polovine odgovarajućeg uzorka divljeg tipa SAP izoliranog iz humanog seruma.
27. Postupak za pripremu humanog SAP polipeptida, naznačen time, da postupak obuhvaća:
i) pribavljanje glikoliziranog humanog SAP polipeptida, pri čemu glikozilirani humani SAP polipeptid sadržava oligosaharidni lanac vezan na N ; i
ii) enzimsku ili kemijsku promjenu oligosaharidnog lanca vezanog na N humanog SAP polipeptida kako bi se dobio modificirani glikozilirani humani SAP polipeptid, pri čemu barem jedna grana oligosaharidnog lanca završava kiselinskom skupinom sijalične kiseline vezanim na α2,3.
28. Postupak u skladu s patentnim zahtjevom 27, naznačen time, da proces enzimske ili kemijske promjene oligosaharidnog lanca vezanog na N SAP polipeptida uklanja jednu ili više završnih skupina sijalične kiseline vezanih na α2,6 iz oligosaharidnog lanca.
29. Postupak u skladu s patentnim zahtjevom 27, naznačen time, da proces enzimske ili kemijske promjene oligosaharidnog lanca vezanog na N humanog SAP polipeptida zamjenjuje jednu ili više završnih skupina sijalične kiselina vezanih na α2,6 oligosaharidnog lanca s jednom ili više skupina sijalične kiselina vezanih na α2,3.
30. Postupak u skladu s bilo kojim od patentnih zahtjeva 27 do 29, naznačen time, da je oligosaharidni lanac vezan na N ima barem 50% manje ostataka sijalične kiselina vezanih na α.2,6 od divljeg tipa humanog SAP proteina izoliranog iz humanog seruma.
31. Postupak u skladu s bilo kojim od patentnih zahtjeva 27 do 29, naznačen time, da su oligosaharidni lanci vezani na N u biti bez kiselinskih ostataka sijalične kiseline vezanih na α2,6.
32. Postupak u skladu s bilo kojim od patentnih zahtjeva 27 do 31, naznačen time, da svi ogranci oligosaharidnih lanaca završavaju skupinama sijalične kiseline vezanim na α2,3.
33. Postupak u skladu s bilo kojim od patentnih zahtjeva 27 do 32, naznačen time, da modificirana glikolizirani SAP polipeptid ima IC50 za inhibiciju diferencijacije monocita u fibrocite in vitro, koja je manja od jedne polovice one od odgovarajućeg uzorka SAP divljeg tipa izoliranog iz humanog seruma.
34. Postupak za pripremu humanog SAP polipeptida, naznačen time, da obuhvaća:
i) pripremu humanog SAP polipeptida i
ii) enzimsku ili kemijsku promjenu humanog SAP polipeptida da bi se proizveo glikozilirani humani SAP polipeptid koji sadržava oligosaharide vezane na N, pri čemu barem jedan ogranak oligosaharidnog lanca 2,3 završava skupinom sijalične kiseline vezanom na α2,3.
35. Humani SAP polipeptid koji sadržava oligosaharidni lanac vezan na N , naznačen time, da najmanje jedan ogranak oligosaharlda završava skupinom sijalične kiseline vezanom na α2,3 koji je pripravljen postupkom koji obuhvaća:
i) ekspresija SAP polipeptida u CHO stanici; i
ii) izolaciju SAP polipeptida iz stanice.
36. Humani SAP polipeptid u skladu s patentnim zahtjevom 35, naznačen time, da SAP polipeptid ima IC50 za inhibiciju diferencijacije monocita u fibrocite in vitro koja je manja od polovine one odgovarajućeg uzorka divljeg tipa SAP izoliranog iz humanog seruma.
37. CHO stanica koja obuhvaća humani SAP polipeptid koji sadržava oligosaharidni lanac vezan na N, naznačen time, da najmanje jedan ogranak oligosahardnog lanca završava kiselinskom skupinom sijalične kiseline vezanim na α2,3.
38. SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 16 za uporabu u liječenju ili sprečavanju stanja ili poremećaja odabranih iz skupine koju čine: upalni poremećaji, fibrozni ili fibroproliferativni poremećaji, poremećaji preosjetljivosti, autoimuni poremećaji ili upalni poremećaji sluznice.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21793109P | 2009-06-04 | 2009-06-04 | |
| PCT/US2010/037542 WO2010141918A1 (en) | 2009-06-04 | 2010-06-04 | Serum amyloid p derivatives and their preparation and use |
| EP10784210.6A EP2438083B1 (en) | 2009-06-04 | 2010-06-04 | Serum amyloid p derivatives and their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160221T1 true HRP20160221T1 (hr) | 2016-03-25 |
Family
ID=43298203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160221T HRP20160221T1 (hr) | 2009-06-04 | 2016-03-01 | Serum amiloidni p derivati i njihova priprema i upotreba |
| HRP20181803TT HRP20181803T1 (hr) | 2009-06-04 | 2018-10-31 | Serumski amiloidni p derivati i njihova priprava i uporaba |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181803TT HRP20181803T1 (hr) | 2009-06-04 | 2018-10-31 | Serumski amiloidni p derivati i njihova priprava i uporaba |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9296800B2 (hr) |
| EP (2) | EP2438083B1 (hr) |
| JP (3) | JP5801293B2 (hr) |
| CN (1) | CN102574902B (hr) |
| AU (1) | AU2010256426B2 (hr) |
| BR (2) | BR122020010980B1 (hr) |
| CA (1) | CA2764461C (hr) |
| CO (1) | CO6480917A2 (hr) |
| CR (1) | CR20110640A (hr) |
| CY (1) | CY1120817T1 (hr) |
| DK (2) | DK2438083T3 (hr) |
| EA (1) | EA030332B1 (hr) |
| ES (2) | ES2692815T3 (hr) |
| HK (1) | HK1168603A1 (hr) |
| HR (2) | HRP20160221T1 (hr) |
| HU (1) | HUE026737T2 (hr) |
| IL (1) | IL216744A (hr) |
| LT (1) | LT3042915T (hr) |
| MX (1) | MX2011012738A (hr) |
| MY (1) | MY158761A (hr) |
| NZ (1) | NZ596849A (hr) |
| PL (2) | PL2438083T3 (hr) |
| PT (1) | PT3042915T (hr) |
| SI (2) | SI3042915T1 (hr) |
| TR (1) | TR201815592T4 (hr) |
| UA (1) | UA110323C2 (hr) |
| WO (1) | WO2010141918A1 (hr) |
| ZA (1) | ZA201108857B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8247370B2 (en) * | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| US9884899B2 (en) * | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| US8497243B2 (en) * | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| CA2755047C (en) | 2009-03-11 | 2018-12-04 | Promedior, Inc. | Treatment methods for autoimmune disorders |
| JP5797565B2 (ja) * | 2009-03-11 | 2015-10-21 | プロメディオール， インコーポレイテッド | 過敏性障害（ｈｙｐｅｒｓｅｎｓｉｔｉｖｅ ｄｉｓｏｒｄｅｒ）に対する処置および診断方法 |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| ES2552793T3 (es) | 2009-06-17 | 2015-12-02 | Promedior Inc. | Variantes de SAP y su uso |
| FR2969153B1 (fr) * | 2010-12-17 | 2014-10-17 | Lab Francais Du Fractionnement | Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee |
| WO2012158672A2 (en) | 2011-05-16 | 2012-11-22 | Polymedix, Inc. | Compounds for use in treatment of mucositis |
| JP6340319B2 (ja) * | 2011-12-21 | 2018-06-06 | プロメディオール， インコーポレイテッド | 血清アミロイドｐ−抗体融合タンパク質 |
| EP3718558A1 (en) * | 2013-10-08 | 2020-10-07 | Promedior, Inc. | Methods for treating fibrotic cancers |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| CN105372214B (zh) * | 2014-08-18 | 2019-06-28 | 中国科学院上海有机化学研究所 | 一种鉴定新红细胞生成刺激蛋白的n-连接寡糖结构的方法 |
| MX2019002734A (es) * | 2016-09-13 | 2019-05-27 | Bayer Healthcare Llc | Glicoformas del factor viia. |
| JP6852397B2 (ja) | 2016-12-28 | 2021-03-31 | 株式会社島津製作所 | 分析用試料の調製方法および分析方法 |
| CN108114001B (zh) * | 2017-12-23 | 2023-05-30 | 中国科学院海洋研究所 | 一种诱导海产双壳贝类产卵的诱导剂及其应用方法 |
| WO2021248008A1 (en) | 2020-06-05 | 2021-12-09 | Innovation Pharmaceuticals Inc. | Arylamide compounds for treatment and prevention of viral infections |
| IL302388A (en) * | 2020-11-02 | 2023-06-01 | Attralus Inc | SAP FC fusion proteins and methods of use |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1562244A (en) * | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
| GB1594389A (en) * | 1977-06-03 | 1981-07-30 | Max Planck Gesellschaft | Dressing material for wounds |
| GB8516081D0 (en) | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
| US6071517A (en) * | 1986-07-07 | 2000-06-06 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
| EP0321703B1 (en) * | 1987-11-20 | 1993-04-28 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Absorbent for serum amyloid protein |
| US7070994B2 (en) * | 1988-03-21 | 2006-07-04 | Oxford Biomedica (Uk) Ltd. | Packaging cells |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5092876A (en) * | 1989-08-30 | 1992-03-03 | The United States Of America As Represented By The Department Of Health And Human Services | Cell attachment peptides derived from amyloid P component |
| EP0587777A4 (en) | 1991-05-31 | 1995-05-10 | New England Deaconess Hospital | CARCINOBRYONARY ANTIGEN BINDING PROTEINS AND METHODS OF ISOLATING AND USING THE SAME. |
| US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
| CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US6054121A (en) * | 1993-02-26 | 2000-04-25 | The Picower Institute For Medical Research | Modulation of immune responses in blood-borne mesenchymal cells |
| US5804446A (en) * | 1993-02-26 | 1998-09-08 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| AU7043694A (en) | 1993-05-27 | 1994-12-20 | Regents Of The University Of Michigan, The | Method of treatment and prevention of immune complex-induced lung injury |
| US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
| GB9317120D0 (en) * | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
| US5981470A (en) | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
| US5989811A (en) * | 1994-09-29 | 1999-11-23 | Urocor, Inc. | Sextant core biopsy predictive mechanism for non-organ confined disease status |
| US6030815A (en) | 1995-04-11 | 2000-02-29 | Neose Technologies, Inc. | Enzymatic synthesis of oligosaccharides |
| US5922577A (en) | 1995-04-11 | 1999-07-13 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
| US5876980A (en) | 1995-04-11 | 1999-03-02 | Cytel Corporation | Enzymatic synthesis of oligosaccharides |
| US5728554A (en) | 1995-04-11 | 1998-03-17 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
| CA2204743C (en) * | 1995-09-13 | 2008-09-02 | Keiji Sakamoto | D-pantolactone hydrolase and gene encoding the same |
| US5750345A (en) | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
| AU712819B2 (en) | 1996-01-25 | 1999-11-18 | Profylakse Aps | Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| AU8525098A (en) | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| US6365570B1 (en) * | 1997-10-10 | 2002-04-02 | Universiteit Utrecht | Pharmaceutical and diagnostic use of Serum Amyloid P component |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| IL137919A0 (en) * | 1998-02-17 | 2001-10-31 | Medarex Inc | Treating and diagnosing macrophage-mediated diseases using fc receptor ligands |
| DE99907899T1 (de) | 1998-03-11 | 2005-01-13 | Kabushiki Kaisha Soken | Hautnormalisierungsmittel |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| JPH11319542A (ja) | 1998-05-08 | 1999-11-24 | Tokuyama Corp | 超薄層の製造方法 |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6600019B2 (en) * | 2000-01-06 | 2003-07-29 | Curagen Corporation | Polypeptides and nucleic acids encoding same |
| EP1267795A1 (en) | 2000-03-30 | 2003-01-02 | Brennen Medical Inc. | Anti-microbial and immunostimulating composition |
| US20040068095A1 (en) * | 2001-03-14 | 2004-04-08 | Shimkets Richard A. | Novel human proteins, polynucleotides encoding them and methods of using the same |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US6872541B2 (en) * | 2001-07-25 | 2005-03-29 | Coulter International Corp. | Method and compositions for analysis of pentraxin receptors as indicators of disease |
| US6537811B1 (en) * | 2001-08-01 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of SAP-1 expression |
| US20030199442A1 (en) | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| JP2004049214A (ja) | 2001-11-29 | 2004-02-19 | Nippon Shokubai Co Ltd | 蛋白質またはペプチドの細胞内導入方法 |
| US7022476B2 (en) * | 2002-02-26 | 2006-04-04 | New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery | Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof |
| GB0211136D0 (en) | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
| US20050182042A1 (en) * | 2002-05-17 | 2005-08-18 | Feldman David L. | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
| JP4819364B2 (ja) * | 2002-12-23 | 2011-11-24 | ウイリアム、マーシュ、ライス、ユーニヴァーサティ | 線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物 |
| US7763256B2 (en) * | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| US8012472B2 (en) * | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
| JP2006526140A (ja) | 2002-12-24 | 2006-11-16 | バイオサイト インコーポレイテッド | 鑑別診断のためのマーカーおよびその使用方法 |
| US20070149450A1 (en) | 2003-02-27 | 2007-06-28 | Ranjit Bhardwaj | Method for reducing levels of c-reactive protein |
| MXPA06011796A (es) | 2004-04-16 | 2007-05-07 | Macrogenics Inc | Anticuerpos especificos de fc(riib y metodos para el uso de los mismos. |
| KR101297146B1 (ko) | 2004-05-10 | 2013-08-21 | 마크로제닉스, 인크. | 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법 |
| WO2006002438A2 (en) | 2004-06-03 | 2006-01-05 | Medarex, Inc. | Human monoclonal antibodies to fc gamma receptor i (cd64) |
| WO2006002930A2 (en) | 2004-06-30 | 2006-01-12 | Friedrich-Alexander- Universitaet Erlangen- Nuernberg | FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS |
| ZA200701783B (en) | 2004-09-02 | 2009-10-28 | Genentech Inc | Anti-Fc-gamma RIIB receptor antibody and uses therefor |
| US7553653B2 (en) * | 2004-09-17 | 2009-06-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| WO2006039418A2 (en) | 2004-09-30 | 2006-04-13 | Medarex, Inc. | Human monoclonal antibodies to fc gamma receptor ii (cd32) |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US20070099251A1 (en) | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070243163A1 (en) | 2006-02-17 | 2007-10-18 | Chih-Ping Liu | Respiratory tract delivery of interferon-tau |
| US8247370B2 (en) * | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| US8497243B2 (en) * | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| ES2554167T3 (es) | 2007-07-06 | 2015-12-16 | Promedior Inc. | Métodos y composiciones útiles en el tratamiento de mucositis |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| JP5797565B2 (ja) * | 2009-03-11 | 2015-10-21 | プロメディオール， インコーポレイテッド | 過敏性障害（ｈｙｐｅｒｓｅｎｓｉｔｉｖｅ ｄｉｓｏｒｄｅｒ）に対する処置および診断方法 |
| CA2755047C (en) * | 2009-03-11 | 2018-12-04 | Promedior, Inc. | Treatment methods for autoimmune disorders |
| US20100266643A1 (en) | 2009-04-01 | 2010-10-21 | Willett W Scott | Pulmonary and nasal delivery of serum amyloid p |
| UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| ES2552793T3 (es) * | 2009-06-17 | 2015-12-02 | Promedior Inc. | Variantes de SAP y su uso |
-
2010
- 2010-04-06 UA UAA201115614A patent/UA110323C2/ru unknown
- 2010-06-04 EA EA201171490A patent/EA030332B1/ru unknown
- 2010-06-04 MY MYPI2011005861A patent/MY158761A/en unknown
- 2010-06-04 PT PT15197076T patent/PT3042915T/pt unknown
- 2010-06-04 EP EP10784210.6A patent/EP2438083B1/en active Active
- 2010-06-04 US US12/794,132 patent/US9296800B2/en active Active
- 2010-06-04 MX MX2011012738A patent/MX2011012738A/es active IP Right Grant
- 2010-06-04 BR BR122020010980-7A patent/BR122020010980B1/pt active IP Right Grant
- 2010-06-04 JP JP2012514212A patent/JP5801293B2/ja active Active
- 2010-06-04 CA CA2764461A patent/CA2764461C/en active Active
- 2010-06-04 CN CN201080028923.8A patent/CN102574902B/zh active Active
- 2010-06-04 TR TR2018/15592T patent/TR201815592T4/tr unknown
- 2010-06-04 NZ NZ596849A patent/NZ596849A/xx unknown
- 2010-06-04 HU HUE10784210A patent/HUE026737T2/en unknown
- 2010-06-04 LT LTEP15197076.1T patent/LT3042915T/lt unknown
- 2010-06-04 PL PL10784210T patent/PL2438083T3/pl unknown
- 2010-06-04 WO PCT/US2010/037542 patent/WO2010141918A1/en active Application Filing
- 2010-06-04 BR BRPI1012924A patent/BRPI1012924B8/pt active IP Right Grant
- 2010-06-04 ES ES15197076.1T patent/ES2692815T3/es active Active
- 2010-06-04 AU AU2010256426A patent/AU2010256426B2/en active Active
- 2010-06-04 SI SI201031760T patent/SI3042915T1/sl unknown
- 2010-06-04 SI SI201031135T patent/SI2438083T1/sl unknown
- 2010-06-04 DK DK10784210.6T patent/DK2438083T3/en active
- 2010-06-04 PL PL15197076T patent/PL3042915T3/pl unknown
- 2010-06-04 DK DK15197076.1T patent/DK3042915T3/en active
- 2010-06-04 ES ES10784210.6T patent/ES2563748T3/es active Active
- 2010-06-04 EP EP15197076.1A patent/EP3042915B1/en active Active
-
2011
- 2011-11-29 CR CR20110640A patent/CR20110640A/es unknown
- 2011-12-01 IL IL216744A patent/IL216744A/en active IP Right Grant
- 2011-12-01 ZA ZA2011/08857A patent/ZA201108857B/en unknown
- 2011-12-21 CO CO11176414A patent/CO6480917A2/es active IP Right Grant
-
2012
- 2012-08-02 HK HK12107623.6A patent/HK1168603A1/zh unknown
-
2015
- 2015-03-27 JP JP2015067656A patent/JP2015120754A/ja active Pending
-
2016
- 2016-03-01 HR HRP20160221T patent/HRP20160221T1/hr unknown
-
2017
- 2017-02-10 JP JP2017023183A patent/JP2017082008A/ja active Pending
- 2017-04-20 US US15/492,085 patent/US20180044387A1/en not_active Abandoned
-
2018
- 2018-10-19 CY CY181101079T patent/CY1120817T1/el unknown
- 2018-10-31 HR HRP20181803TT patent/HRP20181803T1/hr unknown
-
2019
- 2019-12-31 US US16/731,320 patent/US20200369735A1/en not_active Abandoned
-
2020
- 2020-07-28 US US16/941,515 patent/US20210179679A1/en not_active Abandoned
-
2022
- 2022-03-15 US US17/695,071 patent/US20230058309A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160221T1 (hr) | Serum amiloidni p derivati i njihova priprema i upotreba | |
| US20230279048A1 (en) | Compositions containing hc-ha/ptx3 complexes and methods of use thereof | |
| Teixeira et al. | Biological applications of plants and algae lectins: An overview | |
| Ligtenberg et al. | Salivary agglutinin/glycoprotein-340/DMBT1: a single molecule with variable composition and with different functions in infection, inflammation and cancer | |
| JP5057383B2 (ja) | 新規ムチン型糖タンパク質及びその用途 | |
| Sun et al. | An anti-lipopolysaccharide factor from red swamp crayfish, Procambarus clarkii, exhibited antimicrobial activities in vitro and in vivo | |
| KR101569751B1 (ko) | 부분 탈아세틸화 키틴 유도체의 조성물 | |
| CN105555290B (zh) | 抗微生物肽 | |
| AU2002328203B2 (en) | Antimicrobial and anti-inflammatory peptides | |
| Kamel et al. | Novel anti-arthritic mechanisms of Polydatin in complete Freund’s adjuvant-induced arthritis in rats: involvement of IL-6, STAT-3, IL-17, and NF-кB | |
| GB2477914A (en) | Biofilm disruption using microbial nucleases | |
| JP2002544759A (ja) | カチオン性ペプチド単独、または抗生物質と組み合わせて用いて感染を処置するための組成物および方法 | |
| NL2011626C2 (en) | Novel polypeptide and uses thereof. | |
| AU2002328203A1 (en) | Antimicrobial and anti-inflammatory peptides | |
| KR20090027213A (ko) | 개선된 항미생물성 펩타이드 | |
| Shah et al. | Multifaceted applications of ulvan polysaccharides: Insights on biopharmaceutical avenues | |
| CN107312765B (zh) | 一种糖胺聚糖裂解酶及其编码基因与应用 | |
| JP4505631B2 (ja) | ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物 | |
| TWI593704B (zh) | 具有抗病原菌功效的抗菌胜肽及其製藥用途 | |
| Scavello et al. | The antimicrobial peptides secreted by the chromaffin cells of the adrenal medulla link the neuroendocrine and immune systems: From basic to clinical studies | |
| Wang et al. | Antibacterial peptides-loaded bioactive materials for the treatment of bone infection | |
| Fu et al. | Antibacterial, wet adhesive, and healing-promoting nanosheets for the treatment of oral ulcers | |
| JP3903503B2 (ja) | 可溶性ポリペプチド | |
| CN110448676B (zh) | 人α防御素5改造肽在制备中和内毒素药物中的应用 | |
| US8815812B2 (en) | Synthetic arginine substituted peptides and their use |